Publications in collaboration with researchers from Complejo Hospitalario de Toledo (32)

2025

  1. Altered B-cell, plasma cell, and antibody immune profiles in blood of patients with systemic mastocytosis

    Journal of Allergy and Clinical Immunology, Vol. 155, Núm. 2, pp. 628-639

2024

  1. T-cell immune profile in blood of systemic mastocytosis: Association with disease features

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 79, Núm. 7, pp. 1921-1937

2021

  1. COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 5, pp. 2083-2086

  2. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study

    The Lancet Haematology, Vol. 8, Núm. 3, pp. e194-e204

  3. Whole-Exome Sequencing Reveals Recurrent but Heterogeneous Mutational Profiles in Sporadic WHO Grade 1 Meningiomas

    Frontiers in Oncology, Vol. 11

2020

  1. Identification and immunophenotypic characterization of normal and pathological mast cells

    Methods in Molecular Biology (Humana Press Inc.), pp. 331-353

2019

  1. Bone marrow mast cell antibody-targetable cell surface protein expression profiles in systemic mastocytosis

    International Journal of Molecular Sciences, Vol. 20, Núm. 3

2018

  1. Characterization of CD34 + hematopoietic cells in systemic mastocytosis: Potential role in disease dissemination

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, Núm. 6, pp. 1294-1304

  2. Impact of somatic and germline mutations on the outcome of systemic mastocytosis

    Blood Advances, Vol. 2, Núm. 21, pp. 2814-2828

2017

  1. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature

    Oncotarget, Vol. 8, Núm. 40, pp. 68950-68963

2016

  1. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis

    Journal of Allergy and Clinical Immunology, Vol. 137, Núm. 1, pp. 168-178.e1

  2. Diagnosis and classification of mastocytosis in non-specialized versus reference centres: A Spanish Network on Mastocytosis (REMA) study on 122 patients

    British Journal of Haematology, Vol. 172, Núm. 1, pp. 56-63

  3. Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression

    Leukemia, Vol. 30, Núm. 1, pp. 124-130

  4. KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression

    Blood, Vol. 127, Núm. 6, pp. 761-768

2015

  1. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: Diagnostic implications

    Modern Pathology, Vol. 28, Núm. 8, pp. 1138-1149

  2. Ex vivo identification and characterization of a population of CD13high CD105+ CD45- mesenchymal stem cells in human bone marrow

    Stem Cell Research and Therapy, Vol. 6, Núm. 1

  3. The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis

    Journal of Leukocyte Biology, Vol. 97, Núm. 1, pp. 49-59

2014

  1. Flow cytometry in mastocytosis: Utility as a diagnostic and prognostic tool

    Immunology and Allergy Clinics of North America, Vol. 34, Núm. 2, pp. 297-313

  2. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM

    Journal of Allergy and Clinical Immunology, Vol. 133, Núm. 2

2013

  1. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis

    Histopathology, Vol. 63, Núm. 6, pp. 780-787